$CRBP News

Corbus Pharmaceuticals' Last Participant Completes Last Clinical Visit In Its CANYON-1 Phase 1b Clinical Study Of CRB-913 To Treat Obesity

Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer

Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34

Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $52

Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near

Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript

Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $30

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript

HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $40 Price Target

Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO - Slideshow

Corbus Pharma Reports Updated Data From Phase 1/2 Clinical Study Of CRB-701, Next-Gen Nectin-4 Targeted Antibody Drug Conjugate

Mizuho Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $44

Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout

Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

Corbus Pharmaceuticals To Discuss Updated Data For Its Phase 1/2 Trial Of CRB-701 Antibody Drug Candidate To Treat Head And Neck Squamous Cell Carcinoma

Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors

Jefferies Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $33